Sep 30, 2021
Immutep to present Phase II TACTI-002 data at SITC 2021
Sep 28, 2021
Immutep Receives A$3.4 million R&D Tax Incentive from French Government
Immutep to Present at Healthcare Investor Conferences
Sep 20, 2021
Immutep to Present Final Overall Survival Data From Phase IIb AIPAC as a Late Breaking Poster Presentation at SITC 2021
Sep 01, 2021
Immutep Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-002
